BioMarin Pharmaceuticals, Inc. (BMRN) Tops Q2 EPS by 6c; Guides FY11
Tweet
Share
E-mailGet Alerts BMRN Hot Sheet
Price: $55.63 +1.72%
EPS Growth %: -34.0%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: -34.0%
Financial Fact:
Collaborative agreement revenues: 1K
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
BioMarin Pharmaceuticals, Inc. (NASDAQ: BMRN) reported Q2 EPS of ($0.05), $0.06 better than the analyst estimate of ($0.11). Revenue for the quarter came in at $110.63 million versus the consensus estimate of $105.9 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Sees FY2011 revenue of $436-$465 million, versus prior guidance of $422-$452 million and the consensus of $441.08 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Stifel Reiterates Hold Rating on BioMarin Pharmaceutical Inc. (BMRN)
- Accenture tumbles 16% on guidance cut; announces Dragos, runZero, NetRise deals
- PowerFleet, Inc. (AIOT) Misses Q1 EPS by 2c ; Offers Guidance
Create E-mail Alert Related Categories
Earnings, GuidanceSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
